TIMEFOLIO K-Bio Active ETF Achieves Top Returns in South Korea
TIMEFOLIO Asset Management's 'TIMEFOLIO K-Bio Active' Exchange-Traded Fund (ETF) has achieved the highest return among all domestically listed ETFs in the past month, with an impressive gain of 34.89%. This outstanding performance significantly surpassed the KOSPI and KRX Healthcare indices, attributed chiefly to aggressive investments in specific global sectors. TIMEFOLIO intends to maintain its focus on themes centered around obesity, ADC (Antibody-Drug Conjugate), and biotech platforms, actively investing across a diverse range of biotech companies to minimize risks by utilizing technology export and M&A opportunities.
The company's deep research and active portfolio strategy are key factors behind the success. It emphasized attention to the concentration of global capital and R&D in promising themes such as GLP-1 class obesity and metabolic disorder treatments. Looking forward, TIMEFOLIO plans to sustain stable performance by maintaining exposure to these themes. This strategy involves a focus on platform biotech, obesity, and metabolic disorder sectors by increasing the weight of related companies.
Related News
'TIMEFOLIO K Bioactive ETF', Ranked 1st with a 35% 1-Month Return - Smart Today|Smart Today=Reporter Kim Yunjin| TIMEFOLIO Asset Management's 'TIMEFOLIO K Bioactive ETF' recently recorded the highest return among all domestically listed ETFs based on a 1-month performance. According to the Korea Exchange on the 27th, as of the 25th, the TIMEFOLIO K Bioactive ETF had a 1-month return of 34.89%.
TIMEFOLIO K-Bioactive ETF, Top 1-month Return - meconomynews.comTimefolio Asset Management announced on the 27th that the TIMEFOLIO K-Bioactive Exchange-Traded Fund (ETF) recorded a 1-month return of 34.89% as of the 25th, ranking first among all ETFs. The performance is attributed to an active portfolio strategy based on in-depth research. It includes a higher index weight for platform biotechs with global technology export experience, such as Alteogen, ABL Bio, and Rigochem Bio, and companies with pipelines related to obesity and MASH (Metabolic Associated Steatohepatitis), including Olix, D&D Pharmatech, Hanmi Pharmaceutical, and G2G Bio. Additionally, the manager
뉴스핌2025 11月 27
Timefolio Asset Management's 'K Bioactive' ETF Ranked 1st in 1-Month Returns - Newspim[Seoul=Newspim] Reporter Kim Ga-hee - Timefolio Asset Management announced on the 27th that its 'TIMEFOLIO K Bioactive' Exchange Traded Fund (ETF) recorded the highest returns among all domestically listed ETFs in the past month. According to the Korea Exchange, as of the 25th, TIMEF
KOSPI Rises 0.5% While Climbing 35%... TIMEFOLIO's K-Bioactive ETF Ranks 1st in One-Month Returns - Seoul Economic DailySecurities > Domestic Stock Market News: As volatility grows in the domestic bio sector, TIMEFOLIO Asset Management's ‘TIMEFOLIO K-Bioactive’ ETF over the past month...